5/22/2024 | DD | Acorda Therapeutics reports $20.77 million net loss for April
|
5/17/2024 | DD | Acorda Therapeutics seeks OK of $1.3 million employee retention plan
|
5/13/2024 | DD | Acorda files Chapter 11 plan of liquidation, disclosure statement
|
5/3/2024 | DD | Acorda Therapeutics gets final approval of $60 million DIP package
|
4/30/2024 | DD | Acorda Therapeutics gets approval of bid procedures for assets
|
4/23/2024 | DD | Acorda Therapeutics’ $60 million DIP loan draws committee objection
|
4/15/2024 | DD | Acorda Therapeutics’ official committee of unsecured creditors formed
|
4/5/2024 | BKCVDDEMHY | Prospect News reports 10 new defaults for March 28-April 3
|
4/5/2024 | DD | Acorda Therapeutics gets interim approval of $60 million DIP facility
|
4/2/2024 | DD | Acorda Therapeutics details proposed $60 million DIP facility
|
4/1/2024 | CVDD | Acorda Therapeutics files Chapter 11, inks RSA with convertible holders
|
12/24/2019 | CV | Market Commentary: Convertibles trading grinds to a halt; Ares Capital active; Acorda flat after exchange
|
12/24/2019 | CV | Market Commentary: Morning Commentary: Secondary space grinds to a halt; Acorda one of few names on tape
|
12/23/2019 | CVLM | Acorda to exchange $276 million 1.75% convertibles for notes, cash
|
8/2/2019 | CV | Market Commentary: Acorda convertible notes tank post-earnings; Square drops outright; Aphria notes gain
|
8/2/2019 | CV | Market Commentary: Morning Commentary: Acorda convertible notes tank post-earnings, off 9 points outright
|
1/3/2019 | CV | Market Commentary: Apple suppliers Microchip Technology, Western Digital notes active; Ensco better bid
|
9/13/2018 | CV | Market Commentary: International Flavors hits market; DocuSign borrow ‘horrendous’; NXP busy; Acorda down
|
9/11/2018 | CV | Market Commentary: DocuSign on tap; market eyes International Flavors; Integrated Device Technology gains
|
6/8/2018 | CV | Market Commentary: Convertibles primary prices $1.06 billion; Vishay, Mindbody, Exact Sciences active
|
1/19/2018 | CV | Market Commentary: New convertibles from Patrick, Nutanix remain strong; Acorda, NXP, Blackhawk active
|
1/19/2018 | CV | Market Commentary: Morning Commentary: New paper from Patrick, Nutanix strong; Acorda active on buy-out speculation
|
11/15/2017 | DD | Market Commentary: Altice up on debt-cutting plans; energy names off as crude retreat continues; Murray drops as Bowie buyout dies
|
11/15/2017 | HY | Market Commentary: Altice up on debt-cutting plans; energy names off; Murray drops as Bowie buyout dies
|
11/15/2017 | CV | Market Commentary: Rambus eclipses Quotient in trades; Everbridge to price; Emergent dips; Acorda tanks
|
9/1/2017 | CV | Market Commentary: Convertibles quiet ahead of long weekend; Palo Alto Networks up in line; Acorda off lows
|
9/1/2017 | CV | Market Commentary: Morning Commentary: Palo Alto Networks moves up; Acorda Therapeutics recoups a couple of points
|
8/29/2017 | CV | Market Commentary: Acorda convertibles, stock beaten down as FDA sends ‘refusal to file’; Citrix improves
|
8/29/2017 | CV | Market Commentary: Morning Commentary: Acorda convertibles, stock take beating as FDA sends a ‘refusal to file’
|
7/3/2017 | CV | Market Commentary: Micron weakens again; Arconic in recovery mode; Acorda convertibles edge up with stock
|
7/3/2017 | CV | Market Commentary: Morning Commentary: Micron Technology weakens again; Acorda convertibles edge up with stock
|
6/6/2017 | CV | Market Commentary: Microchip higher as guidance raised; Acorda sees positive trial results; DISH gets a penalty
|
5/31/2017 | CV | Market Commentary: NXP convertibles gain as market mulls Qualcomm merger; health care names slip; volume thin
|
4/4/2017 | CV | Market Commentary: Acorda convertibles under pressure; Depomed edges up on debt payment; Gogo goes up
|
4/4/2017 | CV | Market Commentary: Morning Commentary: Acorda Therapeutics convertibles under pressure; Depomed edges up on payment
|
4/3/2017 | CV | Market Commentary: Convertible bond trading limited; Tesla paper rises on shipments; Acorda patents nixed
|
2/10/2017 | CV | Market Commentary: Microchip’s new deals trade ‘around par’ post-pricing; Acorda gains; Immunomedics rises
|
2/10/2017 | CV | Market Commentary: Morning Commentary: Microchip’s new deals trade ‘around par’ post-pricing; Acorda gains momentum
|
5/31/2016 | CV | Market Commentary: Health care in focus as sector lifts; Softbank mandatory exchangeable into Alibaba on tap
|
3/15/2016 | CV | Market Commentary: Valeant woes cast a pall over convertible biotech/health care; energy shows resilience
|
3/15/2016 | CV | Market Commentary: Morning Commentary: Energy names show resilience as oil heads back down; Acorda Therapeutics weaker
|
1/25/2016 | PP | Acorda Therapeutics lines up $75 million private placement of shares
|
1/19/2016 | PP | Acorda plans $75 million private placement of stock, $60 million loan
|
1/11/2016 | CV | Market Commentary: Energy-related convertibles move lower; other sectors hold in on swap; Depomed drops
|
1/11/2016 | CV | Market Commentary: Morning Commentary: Depomed convertibles, shares lower; health care in focus during conference
|
9/8/2015 | CV | Market Commentary: Convertibles see better bidders; Impax up outright with FDA news; Dycom, Stericycle on tap
|
6/30/2015 | CV | Market Commentary: Convertibles lower with month-end in focus; Impax slips below par; June primary falters
|
6/30/2015 | CV | Market Commentary: Morning Commentary: Convertibles lower again with month-end in focus; Isis Pharmaceuticals lower
|
6/24/2015 | CV | Market Commentary: New NRG gains outright, dollar neutral, older NRG in line; CorEnergy edges up; Impax launches
|
6/24/2015 | CV | Market Commentary: Morning Commentary: New NRG improves outright, dollar neutral; older NRG in line; CorEnergy upsizes
|
9/24/2014 | CV | Market Commentary: Tesaro convertibles add outright, dollar neutral on debut; SolarCity stock up on new deal
|
9/11/2014 | PP | Market Commentary: Twitter’s $1.3 billion offering around issue in gray market; WellPoint drops; Tesla slips
|
9/11/2014 | CV | Market Commentary: Twitter’s $1.3 billion offering around issue in gray market; WellPoint drops; Tesla slips
|
6/23/2014 | CV | Acorda greenshoe lifts seven-year 1.75% convertibles to $345 million
|
6/20/2014 | PP | Market Commentary: Intel’s convertible debt rises in active trading; new Acorda 1.75% notes inching higher
|
6/20/2014 | CV | Market Commentary: Intel’s convertible debt rises in active trading; new Acorda 1.75% notes inching higher
|
6/20/2014 | CV | Market Commentary: Morning Commentary: Intel bonds modestly active; Acorda Therapeutics’ new notes firm up
|
6/18/2014 | PP | Market Commentary: Acorda, EZCorp end flat after early weakness; planned Restoration Hardware bid above issue
|
6/18/2014 | CV | Market Commentary: Acorda, EZCorp end flat after early weakness; planned Restoration Hardware bid above issue
|
6/18/2014 | CV | Market Commentary: Morning Commentary: New Acorda adds outright; new EZCorp slips outright; both lag on swap
|
6/18/2014 | CV | New Issue: Acorda Therapeutics sells $300 million seven-year convertibles to yield 1.75%, up 32.5%
|
6/17/2014 | PP | Market Commentary: Three deals on tap; Acorda looks slightly cheap; Restoration Hardware looks slightly rich
|
6/17/2014 | CV | Market Commentary: Three deals on tap; Acorda looks slightly cheap; Restoration Hardware looks slightly rich
|
6/17/2014 | CV | Market Commentary: Morning Commentary: New deals eyed; Acorda looks slightly cheap, Restoration Hardware slightly rich
|
6/16/2014 | CV | Acorda Therapeutics plans $300 million seven-year convertibles to yield 1.75%-2.25%, up 27.5%-32.5%
|
6/16/2014 | PP | Market Commentary: Convertibles quiet; Intel, Tesla in line; Acorda, Restoration Hardware, EZCorp to price
|
6/16/2014 | CV | Market Commentary: Convertibles quiet; Intel, Tesla in line; Acorda, Restoration Hardware, EZCorp to price
|
10/15/2009 | SS | Market Commentary: Reviews unlikely to stop BJ Services buyout; Acorda sparks sale talk; Invesco deal expected
|
5/28/2009 | SS | Acorda Therapeutics shareholder Millenco cuts stake to less than 5%
|
4/13/2009 | SS | Acorda Therapeutics shareholder Millenco reports 4.8% ownership
|
12/12/2008 | SS | Acorda Therapeutics investor Millenco reduces stake to less than 5%
|
8/6/2008 | CVHY | Acorda files automatic shelf registration
|
11/6/2007 | CVHY | Acorda files $150 million shelf
|
5/30/2007 | CVHY | Acorda Therapeutics files $150 million shelf registration
|
5/24/2007 | SS | Third Point sells shares of Acorda, keeps 4.1% stake
|
2/22/2007 | SS | Acorda Therapeutics urged to sell by shareholder Third Point
|
2/22/2007 | SS | Market Commentary: Jupitermedia retreats, Getty off; Acorda seesaws; Trico rises; Iconix up; Nevada Gold gains
|
11/16/2006 | BT | Market Commentary: Elan bonds on tap; Acorda rises on acquisition buzz; Neurochem, CollaGenex, Dendreon sell PIPEs
|
10/17/2006 | BT | Market Commentary: Icos gains 16% on Lilly buyout; Millennium forfeits AnorMED; InterMune rises 25%; OSI better
|
10/6/2006 | BT | Market Commentary: Acorda up 10% as Elan, Biogen ease on Tysabri news; Panacos up on takeover; Memory up on PIPE
|
10/6/2006 | PP | Market Commentary: Memory Pharma PIPE to help complete trials; Access Integrated raises $22 million from notes
|
10/5/2006 | BT | Market Commentary: AnorMED up 7% as Genzyme boosts bid; GenVec gains 18%; Acorda rises; Light Sciences at bat
|
10/5/2006 | PP | Market Commentary: Acorda PIPE boosted cash following disappointing IPO, chief says; Memory secures $31.3 million
|
10/5/2006 | BTPP | New Issue: Acorda Therapeutics gives details of $31.5 million stock sale
|
10/4/2006 | BT | Market Commentary: Acorda off on $31.5 million deal; Dynavax up 13%; Advancis up 8%; AVI falls 7%; Exelixis at bat
|
10/4/2006 | PP | Market Commentary: Acorda secures $31.5 million from stock offering; Dynavax plans $27.28 million direct stock sale
|
10/4/2006 | BTPP | New Issue: Acorda secures $31.5 million from private placement of stock
|
10/3/2006 | BT | Market Commentary: Acorda shoots up 32%; Isis lower after analyst day; Gilead off 3.5%, Myogen eases; Amgen better
|
9/29/2006 | BT | Market Commentary: Exelixis follow-on set for Oct. 2 week; ImaRx on tap; Biomira bounces; Labopharm, Pharmacopeia lower
|
9/25/2006 | BT | Acorda: Study shows Fampridine-SR improves walking in MS patients
|
9/25/2006 | BT | Market Commentary: Acorda skyrockets on trial data; GPC, Pharmion, Spectrum rise; Dendreon steady on rivals' news
|
8/7/2006 | BT | Market Commentary: Encysive sinks on dilution worries; Acorda higher; Genitope gains; Ariad off
|
7/13/2006 | BT | Acorda says current phase 3 trial could serve as primary proof of efficacy for Fampridine-SR
|
7/12/2006 | BT | Acorda may delay results from Fampridine trial until October
|
4/17/2006 | BT | Acorda Therapeutics discloses new results from MS-F202 phase 2 clinical study
|
3/13/2006 | BT | Acorda Therapeutics greenshoe exercised, raising IPO to $36.5 million
|
3/3/2006 | BT | Acorda completes enrollment in trial of Fampridine-SR for multiple sclerosis
|
2/10/2006 | BT | New Issue: Acorda raises $33 million in IPO at $6 per share, low end of revised $6-$7 range
|
2/10/2006 | BT | Market Commentary: Acorda shares close up 12%; Shire better, other ADHD names off on drug labeling; Pfizer slides
|
2/9/2006 | BT | Acorda Therapeutics cuts IPO price talk to $6-$7 per share from $11-$13
|
2/9/2006 | BT | Market Commentary: Acorda IPO on deck with cheaper talk; Serono up on Glaxo chatter; Amylin soars; Charles River rises
|
1/23/2006 | BT | Acorda Therapeutics sets IPO price talk at $11-$13 per share for 5.5 million shares
|
10/5/2005 | BT | Acorda Therapeutics files for $86.25 million initial public offering
|